European Journal of Clinical Pharmacology

, Volume 30, Issue 4, pp 387–392 | Cite as

Tiapamil, a new calcium channel blocking agent for the treatment of effort induced chronic stable angina pectoris

  • N. S. Khurmi
  • C. W. Robinson
  • M. J. O'Hara
  • E. B. Raftery
Originals

Summary

The anti-anginal efficacy of tiapamil, a new calcium channel blocking agent was studied in 24 patients with established effort induced chronic stable angina pectoris. The patients were allocated randomly in a double-blind fashion to tiapamil 300 mg thrice daily or placebo for 2 weeks and thereafter all the patients received tiapamil 300 mg thrice daily in a single-blind fashion for a further 2 weeks. All patients performed symptom limited multistage graded exercise testing with computer-assisted analysis of the electrocardiogram before entering the study and at the end of the double-blind and single-blind phases. The mean exercise time to develop angina during the control test in the group which received placebo during the double-blind phase was 7.1 min; this increased to 8.5 min after 2 weeks of placebo and 9.7 min after 2 weeks of subsequent tiapamil therapy. Similarly in the group which received tiapamil during the double-blind phase the mean exercise time on control test was 6.4 min, increasing to 9.7 min and 9.7 min after 2 and 4 weeks of tiapamil therapy respectively. There were no statistical significant differences between the changes from control, seen with tiapamil and placebo during the double-blind phase. However, the changes observed between control and active therapy in the tiapamil group did reach statistical significance (p=0.003). Similarly, 1 mm ST-segment depression time was prolonged by tiapamil therapy. The heart rate at rest and maximal exercise remained unaltered with tiapamil therapy. Two patients were withdrawn during tiapamil therapy; one developed unstable angina and the other a skin rash which resolved completely after withdrawing the drug. Another patient showed raised liver enzymes after 4 weeks of tiapamil therapy. These results indicate that tiapamil merits further evaluation for the treatment of effort induced chronic stable angina pectoris.

Key words

calcium channel blocking agents tiapamil exercise testing coronary artery disease stable angina pectoris 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Krikler DM, Rowland E (1983) Clinical value of calcium antagonists in treatment of cardiovascular disorders. J Am Coll Cardiol, 1: 355–364Google Scholar
  2. 2.
    Antman EM, Stone PH, Muller JE, Braunwald E (1980) Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. Ann Intern Med 93: 875–885Google Scholar
  3. 3.
    Severi S, Davies GJ, Maseri A, Marzullo P, L'Abbate A (1980) Long term prognosis of ‘variant’ angina with medical treatment. Am J Cardiol 46: 226–232Google Scholar
  4. 4.
    Pepine CJ, Feldman RL, Hill JA, Conti CR, Mehta J, Hill C, Scott E, Gainesville RN (1983) Clinical outcome after treatment of rest angina with calcium blockers: Comparative experience during the initial year of therapy with diltiazem, nifedipine and verapamil. Am Heart J 106: 1341–1347Google Scholar
  5. 5.
    Subramanian VB, Bowles MJ, Khurmi NS, Davies AB, Raftery EB (1984) Evaluation of verapamil and high dose nifedipine in patients with chronic stable angina with objective methods. Acta Medica Scandinavica [Suppl 681]: 61–73Google Scholar
  6. 6.
    Subramanian VB, Khurmi NS, Bowles MJ, O'Hara M, Raftery EB (1983) Objective evaluation of three dose levels of diltiazem in patients with chronic stable angina. J Am Coll Cardiol 1: 1144–1153Google Scholar
  7. 7.
    Khurmi NS, O'Hara MJ, Bowles MJ, Subramanian VB, Raftery EB (1984) Randomized double-blind comparison of gallopamil and propranolol in stable angina pectoris. Am J Cardiol 53: 684–688Google Scholar
  8. 8.
    Khurmi NS, Bowles MJ, Subramanian VB, Raftery EB (1984) Short- and long-term efficacy of nicardipine, assessed by placebo-controlled single- and double-blind crossover trials in patients with chronic stable angina. J Am Coll Cardiol 4: 908–917Google Scholar
  9. 9.
    Khurmi NS, Bowles MJ, O'Hara MJ, Subramanian VB, Raftery EB (1984) Long-term efficacy of diltiazem assessed with multistage graded exercise tests in patients with chronic stable angina pectoris. Am J Cardiol 54: 738–743Google Scholar
  10. 10.
    Gould BA, Mann S, Kieso H, Subramanian VB, Raftery EB (1982) The 24 hour ambulatory blood pressure profile with verapamil. Circulation 65: 22–27Google Scholar
  11. 11.
    Hornung RS, Gould BA, Jones RI, Sonecha TN, Raftery EB (1983) Nifedipine tablets for systemic hypertension: A study using continuous ambulatory intra-arterial recording. Am J Cardiol 51: 1323–1327Google Scholar
  12. 12.
    Jones RI, Hornung RS, Sonecha TN, Raftery EB (1983) The effect of a new calcium channel blocker nicardipine on 24-hour ambulatory blood pressure and the pressor response to isometric and dynamic exercise. J Hypertens 1: 85–89Google Scholar
  13. 13.
    Rosing DR, Condit JR, Maron BJ, Kent KM, Leon MB, Bonow RO, Lipson LC, Epstein SE (1981) Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. III Effects of Long term administration. Am J Cardiol 48: 545–553Google Scholar
  14. 14.
    Hopf R, Kaltenbach M, Kober G (1981) Verapamil in the treatment of hypertrophic obstructive cardiomyopathy. In: Zanchetti A, Krikler DM (eds) Calcium antagonism in cardiovascular therapy. Experience with verapamil. Excerpta Medica, Amsterdam, pp 353–362Google Scholar
  15. 15.
    Bopp P, Merier G, Scheidegger D, Gabathuler J, Rutishanser W (1982) Acute hemodynamic effects of intravenous tiapamil in patients with coronary artery disease. Cardiology 69 [Suppl 1]: 91–98Google Scholar
  16. 16.
    Brisse B, Bender F, Bramann H, Kuhs H, Schwippe G (1982) Management of cardiac arrhythmias with tiapamil. Cardiology, 69 [Suppl 1]: 144–148Google Scholar
  17. 17.
    Gerold M, Eigenmann R, Hausler G (1982) Cardiovascular effects of tiapamil (RO-11-1781), a new calcium entry blocker. J Cardiovasc Pharmacol 4: 419–429Google Scholar
  18. 18.
    Henry PD (1980) Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol 46: 1047–1058Google Scholar
  19. 19.
    Hausler G, Eigenmann R, Gerold M, Hefti F, Jovanovic D, Blaber L, Nakamura K, Thorens S (1982) Overview on the pharmacological and toxicological characterization of the calcium antagonist tiapamil. Cardiology 69 [Suppl 1]: 31–57Google Scholar
  20. 20.
    Harada S, Sada H, Kojima M, Ban T (1982) Negative ionotropic effects of tiapamil (RO-11-1781) and verapamil in rabbit myocardium. Eur J Pharmacol 78: 7–14Google Scholar
  21. 21.
    Campeau L (1976) Grading of angina pectoris (Letter) Circulation 54: 522–523Google Scholar
  22. 22.
    Khurmi NS, Bowles MJ, O'Hara MJ, Robinson CW, Raftery EB (1984) Reproducibility of multistage graded exercise testing in patients with chronic stable angina. Int J Cardiol 6: 137–146Google Scholar
  23. 23.
    Khurmi NS, Bowles MJ, O'Hara MJ, Lahiri A, Raftery EB (1985) Ambulatory monitoring and exercise testing in the evaluation of a new long-acting calcium ion antagonist KB-944 (Fostedil) for the treatment of exertional angina pectoris. Int J Cardiol 9: 289–302Google Scholar
  24. 24.
    Khurmi NS, Bowles MJ, O'Hara MJ, Raftery EB (1986) Effect of propranolol on indices of intermittent myocardial ischemia, assessed by exercise testing and ambulatory ST-segment monitoring. Clin Cardiol (in press)Google Scholar
  25. 25.
    Ellestad MH, Blomqvist CG, Naughton JP (1979) Standards for adult exercise testing laboratories. Circulation 58: 421A-430AGoogle Scholar
  26. 26.
    Fleckenstein A (1977) Specific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle. Ann Rev Pharmacol Toxicol 17: 149–166Google Scholar
  27. 27.
    O'Hara MJ, Khurmi NS, Bowles MJ, Subramanian VB, Dore CJ, Raftery EB (1984) Comparison of diltiazem at two dose levels with propranolol for treatment of stable angina pectoris. Am J Cardiol 54: 477–481Google Scholar
  28. 28.
    O'Hara MJ, Khurmi NS, Bowles MJ, Raftery EB (1985) Objective evaluation of PY-108-068, a new calcium channel inhibitor for the treatment of chronic stable angina pectoris. Eur Heart J 6: 689–694Google Scholar
  29. 29.
    Bowles MJ, Khurmi NS, O'Hara MJ, Raftery EB (1986) Randomized double-blind placebo-controlled comparison of Nicardipine and nifedipine in patients with chronic stable angina pectoris. Chest 89: 260–265Google Scholar
  30. 30.
    Brodsky SJ, Cutler SS, Weiner DA, Klein MD (1981) Hepatotoxicity due to treatment with verapamil. Ann Intern Med 94: 490–491Google Scholar
  31. 31.
    Guarascio P, D'Amato C, Sette P, Conte A, Visco G (1984) Liver damage from verapamil. Br Med J 288: 362–363Google Scholar
  32. 32.
    Khurmi NS, Bowles MJ, Kohli RS, Raftery EB (1986) Does placebo improve indexes of effort-induced myocardial ischemia? An objective study in 150 patients with chronic stable angina pectoris. Am J Cardiol 57: 907–911Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • N. S. Khurmi
    • 1
  • C. W. Robinson
    • 1
  • M. J. O'Hara
    • 1
  • E. B. Raftery
    • 1
  1. 1.The Cardiology Department and the Division of Clinical SciencesNorthwick Park Hospital and Clinical Research CentreHarrowGreat Britain

Personalised recommendations